{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:06:30Z","timestamp":1793815590979,"version":"4.6.1"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41380-025-03387-1","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T05:39:15Z","timestamp":1766209155000},"page":"2685-2697","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The serotonin 1B receptor is required for some of the behavioral effects of psilocybin in mice"],"prefix":"10.1038","volume":"31","author":[{"given":"Sixtine","family":"Fleury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5249-2380","authenticated-orcid":false,"given":"Katherine M.","family":"Nautiyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,20]]},"reference":[{"key":"3387_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/mpr.1359","volume":"21","author":"RC Kessler","year":"2012","unstructured":"Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. 2012;21:169\u201384.","journal-title":"Int J Methods Psychiatr Res"},{"key":"3387_CR2","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1176\/ps.2009.60.11.1439","volume":"60","author":"BN Gaynes","year":"2009","unstructured":"Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv Wash DC. 2009;60:1439\u201345.","journal-title":"Psychiatr Serv Wash DC"},{"key":"3387_CR3","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384:1402\u201311.","journal-title":"N Engl J Med"},{"key":"3387_CR4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3:619\u201327.","journal-title":"Lancet Psychiatry"},{"key":"3387_CR5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78:481.","journal-title":"JAMA Psychiatry"},{"key":"3387_CR6","doi-asserted-by":"publisher","first-page":"112749","DOI":"10.1016\/j.psychres.2020.112749","volume":"284","author":"SB Goldberg","year":"2020","unstructured":"Goldberg SB, Pace BT, Nicholas CR, Raison CL, Hutson PR. The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry Res. 2020;284:112749.","journal-title":"Psychiatry Res"},{"key":"3387_CR7","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387:1637\u201348.","journal-title":"N Engl J Med"},{"key":"3387_CR8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41573-022-00421-7","volume":"21","author":"TD McClure-Begley","year":"2022","unstructured":"McClure-Begley TD, Roth BL. The promises and perils of psychedelic pharmacology for psychiatry. Nat Rev Drug Discov. 2022;21:463\u201373.","journal-title":"Nat Rev Drug Discov"},{"key":"3387_CR9","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s13311-017-0542-y","volume":"14","author":"MW Johnson","year":"2017","unstructured":"Johnson MW, Griffiths RR. Potential therapeutic effects of psilocybin. Neurotherapeutics. 2017;14:734\u201340.","journal-title":"Neurotherapeutics"},{"key":"3387_CR10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","volume":"235","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl). 2018;235:399\u2013408.","journal-title":"Psychopharmacology (Berl)"},{"key":"3387_CR11","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol (Oxf). 2016;30:1181\u201397.","journal-title":"J Psychopharmacol (Oxf)"},{"key":"3387_CR12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/02698811211073759","volume":"36","author":"N Gukasyan","year":"2022","unstructured":"Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. J Psychopharmacol (Oxf). 2022;36:151\u20138.","journal-title":"J Psychopharmacol (Oxf)"},{"key":"3387_CR13","doi-asserted-by":"publisher","first-page":"101809","DOI":"10.1016\/j.eclinm.2022.101809","volume":"56","author":"R Von Rotz","year":"2023","unstructured":"Von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K, et al. Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine. 2023;56:101809.","journal-title":"eClinicalMedicine"},{"key":"3387_CR14","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","volume":"330","author":"CL Raison","year":"2023","unstructured":"Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA. 2023;330:843\u201353.","journal-title":"JAMA"},{"key":"3387_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109504","volume":"231","author":"AB Wulff","year":"2023","unstructured":"Wulff AB, Nichols CD, Thompson SM. Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders. Neuropharmacology. 2023;231:109504.","journal-title":"Neuropharmacology"},{"key":"3387_CR16","doi-asserted-by":"crossref","unstructured":"Chiu YT, Deutch AY, Wang W, Schmitz GP, Huang KL, Kocak DD, et al. A suite of engineered mice for interrogating psychedelic drug actions. BioRxiv Prepr Serv Biol. 2023; 2023.09.25.559347.","DOI":"10.1101\/2023.09.25.559347"},{"key":"3387_CR17","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","volume":"44","author":"MK Madsen","year":"2019","unstructured":"Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Stenb\u00e6k DS, Kristiansen S, et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology. 2019;44:1328\u201334.","journal-title":"Neuropsychopharmacology"},{"key":"3387_CR18","doi-asserted-by":"crossref","unstructured":"Roseman L, Nutt DJ, Carhart-Harris RL Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol [Internet]. 2018 [cited 2024 Oct 2];8. Available from: https:\/\/www.frontiersin.org\/journals\/pharmacology\/articles\/10.3389\/fphar.2017.00974\/full.","DOI":"10.3389\/fphar.2017.00974"},{"key":"3387_CR19","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","volume":"4","author":"DB Yaden","year":"2021","unstructured":"Yaden DB, Griffiths RR. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci. 2021;4:568\u201372.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"3387_CR20","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.cell.2022.12.020","volume":"186","author":"RH Gumpper","year":"2023","unstructured":"Gumpper RH, Roth BL. SnapShot: psychedelics and serotonin receptor signaling. Cell. 2023;186:232\u2013232.e1.","journal-title":"Cell"},{"key":"3387_CR21","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.cell.2020.08.024","volume":"182","author":"K Kim","year":"2020","unstructured":"Kim K, Che T, Panova O, DiBerto JF, Lyu J, Krumm BE, et al. Structure of a hallucinogen-activated Gq-Coupled 5-HT2A serotonin receptor. Cell. 2020;182:1574\u2013.e19.","journal-title":"Cell"},{"key":"3387_CR22","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1021\/acschemneuro.2c00718","volume":"14","author":"LP Cameron","year":"2023","unstructured":"Cameron LP, Patel SD, Vargas MV, Barragan EV, Saeger HN, Warren HT, et al. 5-HT2ARs mediate therapeutic behavioral effects of psychedelic tryptamines. ACS Chem Neurosci. 2023;14:351\u20138.","journal-title":"ACS Chem Neurosci"},{"key":"3387_CR23","doi-asserted-by":"publisher","first-page":"e2022489118","DOI":"10.1073\/pnas.2022489118","volume":"118","author":"N Hesselgrave","year":"2021","unstructured":"Hesselgrave N, Troppoli TA, Wulff AB, Cole AB, Thompson SM. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci. 2021;118:e2022489118.","journal-title":"Proc Natl Acad Sci"},{"key":"3387_CR24","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1021\/acschemneuro.9b00493","volume":"11","author":"M Hibicke","year":"2020","unstructured":"Hibicke M, Landry AN, Kramer HM, Talman ZK, Nichols CD. Psychedelics, but not ketamine, produce persistent antidepressant-like effects in a rodent experimental system for the study of depression. ACS Chem Neurosci. 2020;11:864\u201371.","journal-title":"ACS Chem Neurosci"},{"key":"3387_CR25","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"C Ly","year":"2018","unstructured":"Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23:3170\u201382.","journal-title":"Cell Rep"},{"key":"3387_CR26","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41386-024-01794-6","volume":"49","author":"M Sekssaoui","year":"2024","unstructured":"Sekssaoui M, Bockaert J, Marin P, B\u00e9camel C. Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player? Neuropsychopharmacology. 2024;49:747\u201356.","journal-title":"Neuropsychopharmacology"},{"key":"3387_CR27","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1021\/acsptsci.3c00123","volume":"6","author":"NT Jones","year":"2023","unstructured":"Jones NT, Zahid Z, Grady SM, Sultan ZW, Zheng Z, Razidlo J, et al. Transient elevation of plasma glucocorticoids supports psilocybin-induced anxiolysis in mice. ACS Pharmacol Transl Sci. 2023;6:1221\u201331.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"3387_CR28","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/s41593-022-01177-4","volume":"25","author":"AC Kwan","year":"2022","unstructured":"Kwan AC, Olson DE, Preller KH, Roth BL. The neural basis of psychedelic action. Nat Neurosci. 2022;25:1407\u201319.","journal-title":"Nat Neurosci"},{"key":"3387_CR29","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","volume":"109","author":"LX Shao","year":"2021","unstructured":"Shao LX, Liao C, Gregg I, Davoudian PA, Savalia NK, Delagarza K, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021;109:2535\u2013.e4.","journal-title":"Neuron"},{"key":"3387_CR30","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","volume":"26","author":"Moliner R","year":"2023","unstructured":"Moliner R, Girych M, Brunello CA, Kovaleva V, Biojone C, Enkavi G, et al. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023;26:1032\u201341.","journal-title":"Nat Neurosci"},{"key":"3387_CR31","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.neuropharm.2011.01.017","volume":"61","author":"AL Halberstadt","year":"2011","unstructured":"Halberstadt AL, Geyer MA. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology. 2011;61:364\u201381.","journal-title":"Neuropharmacology"},{"key":"3387_CR32","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nn.3355","volume":"16","author":"X Cai","year":"2013","unstructured":"Cai X, Kallarackal AJ, Kvarta MD, Goluskin S, Gaylor K, Bailey AM, et al. Local potentiation of excitatory synapses by serotonin and its alteration in rodent models of depression. Nat Neurosci. 2013;16:464\u201372.","journal-title":"Nat Neurosci"},{"key":"3387_CR33","doi-asserted-by":"publisher","first-page":"7402","DOI":"10.1523\/JNEUROSCI.6250-10.2011","volume":"31","author":"BN Mathur","year":"2011","unstructured":"Mathur BN, Capik NA, Alvarez VA, Lovinger DM. Serotonin induces long-term depression at corticostriatal synapses. J Neurosci. 2011;31:7402\u201311.","journal-title":"J Neurosci"},{"key":"3387_CR34","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.brainres.2004.01.070","volume":"1007","author":"MS Clark","year":"2004","unstructured":"Clark MS, Vincow ES, Sexton TJ, Neumaier JF. Increased expression of 5-HT1B receptor in dorsal raphe nucleus decreases fear-potentiated startle in a stress dependent manner. Brain Res. 2004;1007:86\u201397.","journal-title":"Brain Res"},{"key":"3387_CR35","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1038\/npp.2016.109","volume":"41","author":"KM Nautiyal","year":"2016","unstructured":"Nautiyal KM, Tritschler L, Ahmari SE, David DJ, Gardier AM, Hen R. A Lack of serotonin 1B autoreceptors results in decreased anxiety and depression-related behaviors. Neuropsychopharmacology. 2016;41:2941\u201350.","journal-title":"Neuropsychopharmacology"},{"key":"3387_CR36","doi-asserted-by":"publisher","first-page":"10856","DOI":"10.1523\/JNEUROSCI.22-24-10856.2002","volume":"22","author":"JF Neumaier","year":"2002","unstructured":"Neumaier JF, Vincow ES, Arvanitogiannis A, Wise RA, Carlezon WA. Elevated expression of 5-HT1B receptors in nucleus accumbens efferents sensitizes animals to cocaine. J Neurosci. 2002;22:10856\u201363.","journal-title":"J Neurosci"},{"key":"3387_CR37","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s00213-016-4225-x","volume":"233","author":"D Aronsen","year":"2016","unstructured":"Aronsen D, Bukholt N, Schenk S. Repeated administration of the 5-HT\u2081B\/\u2081A agonist, RU 24969, facilitates the acquisition of MDMA self-administration: role of 5-HT\u2081A and 5-HT\u2081B receptor mechanisms. Psychopharmacology (Berl). 2016;233:1339\u201347.","journal-title":"Psychopharmacology (Berl)"},{"key":"3387_CR38","doi-asserted-by":"crossref","unstructured":"du Jardin KG, Liebenberg N, Cajina M, M\u00fcller HK, Elfving B, Sanchez C, et al. S-Ketamine mediates its acute and sustained antidepressant-like activity through a 5-HT1B receptor dependent mechanism in a genetic rat model of depression. Front Pharmacol [Internet]. 2018 [cited 2024 Oct 2];8. Available from: https:\/\/www.frontiersin.org\/journals\/pharmacology\/articles\/10.3389\/fphar.2017.00978\/full.","DOI":"10.3389\/fphar.2017.00978"},{"key":"3387_CR39","doi-asserted-by":"publisher","first-page":"eaaw6435","DOI":"10.1126\/scitranslmed.aaw6435","volume":"11","author":"BD Heifets","year":"2019","unstructured":"Heifets BD, Salgado JS, Taylor MD, Hoerbelt P, Cardozo Pinto DF, Steinberg EE, et al. Distinct neural mechanisms for the prosocial and rewarding properties of MDMA. Sci Transl Med. 2019;11:eaaw6435.","journal-title":"Sci Transl Med"},{"key":"3387_CR40","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s002130050819","volume":"141","author":"K Scearce-Levie","year":"1999","unstructured":"Scearce-Levie K, Viswanathan SS, Hen R. Locomotor response to MDMA is attenuated in knockout mice lacking the 5-HT1B receptor. Psychopharmacology (Berl). 1999;141:154\u201361.","journal-title":"Psychopharmacology (Berl)"},{"key":"3387_CR41","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1038\/tp.2013.112","volume":"4","author":"H Yamanaka","year":"2014","unstructured":"Yamanaka H, Yokoyama C, Mizuma H, Kurai S, Finnema SJ, Halldin C, et al. A possible mechanism of the nucleus accumbens and ventral pallidum 5-HT1B receptors underlying the antidepressant action of ketamine: a PET study with macaques. Transl Psychiatry. 2014;4:e342\u2013e342.","journal-title":"Transl Psychiatry"},{"key":"3387_CR42","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.neuron.2015.03.041","volume":"86","author":"KM Nautiyal","year":"2015","unstructured":"Nautiyal KM, Tanaka KF, Barr MM, Tritschler L, Le Dantec Y, David DJ, et al. Distinct circuits underlie the effects of 5-HT1B receptors on aggression and impulsivity. Neuron. 2015;86:813\u201326.","journal-title":"Neuron"},{"key":"3387_CR43","doi-asserted-by":"publisher","first-page":"109686","DOI":"10.1016\/j.isci.2024.109686","volume":"27","author":"R Harari","year":"2024","unstructured":"Harari R, Chatterjee I, Getselter D, Elliott E. Psilocybin induces acute anxiety and changes in amygdalar phosphopeptides independently from the 5-HT2A receptor. iScience. 2024;27:109686 https:\/\/www.cell.com\/iscience\/abstract\/S2589-0042(24)00908-8.","journal-title":"iScience"},{"key":"3387_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2024.110280","volume":"266","author":"M Farinha-Ferreira","year":"2025","unstructured":"Farinha-Ferreira M, Miranda-Louren\u00e7o C, Galipeau C, Lenkei Z, Sebasti\u00e3o AM. Concurrent stress modulates the acute and post-acute effects of psilocybin in a sex-dependent manner. Neuropharmacology. 2025;266:110280.","journal-title":"Neuropharmacology"},{"key":"3387_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-023-02456-9","volume":"13","author":"S Singh","year":"2023","unstructured":"Singh S, Botvinnik A, Shahar O, Wolf G, Yakobi C, Saban M, et al. Effect of psilocybin on marble burying in ICR mice: role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder. Transl Psychiatry. 2023;13:1\u20137.","journal-title":"Transl Psychiatry"},{"key":"3387_CR46","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s002130100778","volume":"157","author":"RM de Almeida","year":"2001","unstructured":"de Almeida RM, Nikulina EM, Faccidomo S, Fish EW, Miczek KA. Zolmitriptan \u2013 a 5-HT1B\/D agonist, alcohol, and aggression in mice. Psychopharmacology (Berl). 2001;157:131\u201341.","journal-title":"Psychopharmacology (Berl)"},{"key":"3387_CR47","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/sj.npp.1300662","volume":"30","author":"G Conductier","year":"2005","unstructured":"Conductier G, Crosson C, Hen R, Bockaert J, Compan V. 3,4-N-Methlenedioxymethamphetamine-induced hypophagia is maintained in 5-HT1B receptor knockout mice, but suppressed by the 5-HT2C receptor antagonist RS102221. Neuropsychopharmacology. 2005;30:1056\u201363.","journal-title":"Neuropsychopharmacology"},{"key":"3387_CR48","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/0166-4328(96)00089-7","volume":"73","author":"M Skingle","year":"1995","unstructured":"Skingle M, Beattie DT, Scopes DIC, Starkey SJ, Connor HE, Feniuk W, et al. GR127935: a potent and selective 5-HT1D receptor antagonist. Behav Brain Res. 1995;73:157\u201361.","journal-title":"Behav Brain Res"},{"key":"3387_CR49","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/PL00004964","volume":"355","author":"P De Vries","year":"1997","unstructured":"De Vries P, Apaydin S, Villal\u00f3n CM, Heiligers JP, Saxena PR. Interactions of GR127935, a 5-HT(1B\/D) receptor ligand, with functional 5-HT receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997;355:423\u201330.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"3387_CR50","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1007\/s00213-020-05521-z","volume":"237","author":"A Dieterich","year":"2020","unstructured":"Dieterich A, Stech K, Srivastava P, Lee J, Sharif A, Samuels BA. Chronic corticosterone shifts effort-related choice behavior in male mice. Psychopharmacology (Berl). 2020;237:2103\u201310.","journal-title":"Psychopharmacology (Berl)"},{"key":"3387_CR51","doi-asserted-by":"crossref","unstructured":"Terstege DJ, Oboh DO, Epp JR FASTMAP: open-source flexible atlas segmentation tool for multi-area processing of biological images. eNeuro [Internet]. 2022 [cited 2023 May 26];9. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8938980\/.","DOI":"10.1523\/ENEURO.0325-21.2022"},{"key":"3387_CR52","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0006-8993(97)01566-7","volume":"790","author":"ME Castro","year":"1998","unstructured":"Castro ME, Pascual J, Rom\u00f3n T, Berciano J, Figols J, Pazos A. 5-HT1B receptor binding in degenerative movement disorders. Brain Res. 1998;790:323\u20138.","journal-title":"Brain Res"},{"key":"3387_CR53","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/0028-3908(94)90067-1","volume":"33","author":"AT Bruinvels","year":"1994","unstructured":"Bruinvels AT, Landwehrmeyer B, Gustafson EL, Durkin MM, Mengod G, Branchek TA, et al. Localization of 5-HT1B, 5-HT1D alpha, 5-HT1E and 5-HT1F receptor messenger RNA in rodent and primate brain. Neuropharmacology. 1994;33:367\u201386.","journal-title":"Neuropharmacology"},{"key":"3387_CR54","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","volume":"53","author":"J Gonz\u00e1lez-Maeso","year":"2007","unstructured":"Gonz\u00e1lez-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron. 2007;53:439\u201352.","journal-title":"Neuron"},{"key":"3387_CR55","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.neuropharm.2013.08.025","volume":"77","author":"AL Halberstadt","year":"2014","unstructured":"Halberstadt AL, Geyer MA. Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response. Neuropharmacology. 2014;77:200\u20137.","journal-title":"Neuropharmacology"},{"key":"3387_CR56","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00213-004-1864-0","volume":"176","author":"MD Lee","year":"2004","unstructured":"Lee MD, Somerville EM, Kennett GA, Dourish CT, Clifton PG. Reduced hypophagic effects of d-fenfluramine and the 5-HT2C receptor agonist mCPP in 5-HT1B receptor knockout mice. Psychopharmacology (Berl). 2004;176:39\u201349.","journal-title":"Psychopharmacology (Berl)"},{"key":"3387_CR57","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1007\/s00213-021-05944-2","volume":"238","author":"SS Desrochers","year":"2021","unstructured":"Desrochers SS, Lesko EK, Magalong VM, Balsam PD, Nautiyal KM. A role for reward valuation in the serotonergic modulation of impulsivity. Psychopharmacology (Berl). 2021;238:3293\u2013309.","journal-title":"Psychopharmacology (Berl)"},{"key":"3387_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49741-9","volume":"15","author":"DP Effinger","year":"2024","unstructured":"Effinger DP, Hoffman JL, Mott SE, Magee SN, Quadir SG, Rollison CS, et al. Increased reactivity of the paraventricular nucleus of the hypothalamus and decreased threat responding in male rats following psilocin administration. Nat Commun. 2024;15:5321.","journal-title":"Nat Commun"},{"key":"3387_CR59","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1038\/s41386-023-01613-4","volume":"48","author":"DR Rijsketic","year":"2023","unstructured":"Rijsketic DR, Casey AB, Barbosa DAN, Zhang X, Hietamies TM, Ramirez-Ovalle G, et al. UNRAVELing the synergistic effects of psilocybin and environment on brain-wide immediate early gene expression in mice. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2023;48:1798\u2013807.","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"key":"3387_CR60","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1021\/acschemneuro.2c00637","volume":"14","author":"PA Davoudian","year":"2023","unstructured":"Davoudian PA, Shao LX, Kwan AC. Shared and distinct brain regions targeted for immediate early gene expression by ketamine and psilocybin. ACS Chem Neurosci. 2023;14:468\u201380.","journal-title":"ACS Chem Neurosci"},{"key":"3387_CR61","doi-asserted-by":"publisher","first-page":"123","DOI":"10.12688\/f1000research.9736.1","volume":"6","author":"KM Nautiyal","year":"2017","unstructured":"Nautiyal KM, Hen R. Serotonin receptors in depression: from A to B. F1000Research. 2017;6:123.","journal-title":"F1000Research"},{"key":"3387_CR62","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s00213-018-4872-1","volume":"235","author":"M Tiger","year":"2018","unstructured":"Tiger M, Varn\u00e4s K, Okubo Y, Lundberg J. The 5-HT1B receptor - a potential target for antidepressant treatment. Psychopharmacology (Berl). 2018;235:1317\u201334.","journal-title":"Psychopharmacology (Berl)"},{"key":"3387_CR63","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0306-4522(94)90164-3","volume":"58","author":"U Boschert","year":"1994","unstructured":"Boschert U, A\u00eft. Amara D, Segu L, Hen R. The mouse 5-hydroxytryptamine 1B receptor is localized predominantly on axon terminals. Neuroscience. 1994;58:167\u201382.","journal-title":"Neuroscience"},{"key":"3387_CR64","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.neubiorev.2004.08.008","volume":"28","author":"Y Sari","year":"2004","unstructured":"Sari Y. Serotonin1B receptors: from protein to physiological function and behavior. Neurosci Biobehav Rev. 2004;28:565\u201382.","journal-title":"Neurosci Biobehav Rev"},{"key":"3387_CR65","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1111\/j.1460-9568.2006.05063.x","volume":"24","author":"H Mizutani","year":"2006","unstructured":"Mizutani H, Hori T, Takahashi T. 5\u2010HT 1B receptor\u2010mediated presynaptic inhibition at the calyx of held of immature rats. Eur J Neurosci. 2006 Oct;24:1946\u201354.","journal-title":"Eur J Neurosci"},{"key":"3387_CR66","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1139\/jpn.0852","volume":"33","author":"F Chenu","year":"2008","unstructured":"Chenu F, David DJP, Leroux-Nicollet I, Le Ma\u00eetre E, Gardier AM, Bourin M. Serotonin1B heteroreceptor activation induces an antidepressant-like effect in mice with an alteration of the serotonergic system. J Psychiatry Neurosci JPN. 2008;33:541\u201350.","journal-title":"J Psychiatry Neurosci JPN"},{"key":"3387_CR67","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature12518","volume":"501","author":"G D\u00f6len","year":"2013","unstructured":"D\u00f6len G, Darvishzadeh A, Huang KW, Malenka RC. Social reward requires coordinated activity of nucleus accumbens oxytocin and serotonin. Nature. 2013;501:179\u201384.","journal-title":"Nature"},{"key":"3387_CR68","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/j.1369-1600.2009.00162.x","volume":"14","author":"NS Pentkowski","year":"2009","unstructured":"Pentkowski NS, Acosta JI, Browning JR, Hamilton EC, Neisewander JL. PRECLINICAL STUDY: stimulation of 5-HT1B receptors enhances cocaine reinforcement yet reduces cocaine-seeking behavior. Addict Biol. 2009;14:419\u201330.","journal-title":"Addict Biol"},{"key":"3387_CR69","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/00008877-200412000-00001","volume":"15","author":"E Tatarczynska","year":"2004","unstructured":"Tatarczynska E, Klodzinska A, Stachowicz K, Chojnacka-W\u00f3jcik E. Effects of a selective 5-HT1B receptor agonist and antagonists in animal models of anxiety and depression. Behav Pharmacol. 2004;15:523.","journal-title":"Behav Pharmacol"},{"key":"3387_CR70","doi-asserted-by":"publisher","first-page":"54ra76","DOI":"10.1126\/scitranslmed.3001079","volume":"2","author":"B Alexander","year":"2010","unstructured":"Alexander B, Warner-Schmidt J, Eriksson T, Tamminga C, Arango-Lievano M, Ghose S, et al. Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens. Sci Transl Med. 2010;2:54ra76.","journal-title":"Sci Transl Med"},{"key":"3387_CR71","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/science.1117571","volume":"311","author":"P Svenningsson","year":"2006","unstructured":"Svenningsson P, Chergui K, Rachleff I, Flajolet M, Zhang X, Yacoubi ME, et al. Alterations in 5-HT1B Receptor Function by p11 in Depression-Like States. Science. 2006;311:77\u201380.","journal-title":"Science"},{"key":"3387_CR72","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.3390\/cells8091018","volume":"8","author":"S Berger","year":"2019","unstructured":"Berger S, Gureczny S, Reisinger SN, Horvath O, Pollak DD. Effect of chronic corticosterone treatment on depression-like behavior and sociability in female and male C57BL\/6N mice. Cells. 2019 Sep;8:1018.","journal-title":"Cells"},{"key":"3387_CR73","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1037\/pha0000112","volume":"25","author":"M Mekiri","year":"2017","unstructured":"Mekiri M, Gardier AM, David DJ, Guilloux JP. Chronic corticosterone administration effects on behavioral emotionality in female c57bl6 mice. Exp Clin Psychopharmacol. 2017;25:94\u2013104.","journal-title":"Exp Clin Psychopharmacol"},{"key":"3387_CR74","doi-asserted-by":"publisher","first-page":"1074633","DOI":"10.3389\/fphar.2022.1074633","volume":"13","author":"K Alper","year":"2022","unstructured":"Alper K, Cange J, Sah R, Schreiber-Gregory D, Sershen H, Vinod KY. Psilocybin sex-dependently reduces alcohol consumption in C57BL\/6J mice. Front Pharmacol. 2022;13:1074633.","journal-title":"Front Pharmacol"},{"key":"3387_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2022.136836","volume":"788","author":"AM Jaster","year":"2022","unstructured":"Jaster AM, Younkin J, Cuddy T, de la Fuente Revenga M, Poklis JL, Dozmorov MG, et al. Differences across sexes on head-twitch behavior and 5-HT2A receptor signaling in C57BL\/6J mice. Neurosci Lett. 2022;788:136836.","journal-title":"Neurosci Lett"},{"key":"3387_CR76","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s00213-021-05913-9","volume":"239","author":"HZ Vohra","year":"2022","unstructured":"Vohra HZ, Saunders JM, Jaster AM, de la Fuente Revenga M, Jimenez J, Fern\u00e1ndez-Teruel A, et al. Sex-specific effects of psychedelics on prepulse inhibition of startle in 129S6\/SvEv mice. Psychopharmacology (Berl). 2022;239:1649\u201364.","journal-title":"Psychopharmacology (Berl)"},{"key":"3387_CR77","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.expneurol.2009.04.008","volume":"218","author":"V Trajkovska","year":"2009","unstructured":"Trajkovska V, Kirkegaard L, Krey G, Marcussen AB, Thomsen MS, Chourbaji S, et al. Activation of glucocorticoid receptors increases 5-HT2A receptor levels. Exp Neurol. 2009;218:83\u201391.","journal-title":"Exp Neurol"},{"key":"3387_CR78","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.neuropharm.2004.10.004","volume":"48","author":"Y Dwivedi","year":"2005","unstructured":"Dwivedi Y, Mondal AC, Payappagoudar GV, Rizavi HS. Differential regulation of serotonin (5HT)2A receptor mRNA and protein levels after single and repeated stress in rat brain: role in learned helplessness behavior. Neuropharmacology. 2005;48:204\u201314.","journal-title":"Neuropharmacology"},{"key":"3387_CR79","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0006-8993(03)02832-4","volume":"980","author":"L Schiller","year":"2003","unstructured":"Schiller L, J\u00e4hkel M, Kretzschmar M, Brust P, Oehler J. Autoradiographic analyses of 5-HT1A and 5-HT2A receptors after social isolation in mice. Brain Res. 2003;980:169\u201378.","journal-title":"Brain Res"},{"key":"3387_CR80","doi-asserted-by":"publisher","first-page":"110172","DOI":"10.1016\/j.neuropharm.2024.110172","volume":"261","author":"O Alitalo","year":"2024","unstructured":"Alitalo O, Kohtala S, Rosenholm M, Saarreharju R, Gonz\u00e1lez-Hern\u00e1ndez G, Sarparanta M, et al. Nitrous oxide induces hypothermia and TrkB activation: Maintenance of body temperature abolishes antidepressant-like effects in mice. Neuropharmacology. 2024;261:110172.","journal-title":"Neuropharmacology"},{"key":"3387_CR81","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s002130000659","volume":"154","author":"S Oerther","year":"2001","unstructured":"Oerther S, Ahlenius S. Involvement of 5-HT1A and 5-HT1B receptors for citalopram-induced hypothermia in the rat. Psychopharmacology (Berl). 2001;154:429\u201334.","journal-title":"Psychopharmacology (Berl)"},{"key":"3387_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175019","volume":"926","author":"SA McDougall","year":"2022","unstructured":"McDougall SA, Roe MJ, Robinson JAM, Cotter LL, Gonzalez DJ, Gleason DC, et al. Effects of the serotonin 5-HT1B receptor agonist CP 94253 on the locomotor activity and body temperature of preweanling and adult male and female rats. Eur J Pharmacol. 2022;926:175019.","journal-title":"Eur J Pharmacol"},{"key":"3387_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02414-5","volume":"13","author":"DP Effinger","year":"2023","unstructured":"Effinger DP, Quadir SG, Ramage MC, Cone MG, Herman MA. Sex-specific effects of psychedelic drug exposure on central amygdala reactivity and behavioral responding. Transl Psychiatry. 2023;13:119.","journal-title":"Transl Psychiatry"},{"key":"3387_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuroscience.2024.01.001","volume":"539","author":"D Funk","year":"2024","unstructured":"Funk D, Araujo J, Slassi M, Lanthier J, Atkinson J, Feng D, et al. Effect of a single psilocybin treatment on Fos protein expression in male rat brain. Neuroscience. 2024;539:1\u201311.","journal-title":"Neuroscience"},{"key":"3387_CR85","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/0269881119895520","volume":"34","author":"LJ Mertens","year":"2020","unstructured":"Mertens LJ, Wall MB, Roseman L, Demetriou L, Nutt DJ, Carhart-Harris RL. Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. J Psychopharmacol (Oxf). 2020;34:167\u201380.","journal-title":"J Psychopharmacol (Oxf)"},{"key":"3387_CR86","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.neuropharm.2017.09.013","volume":"126","author":"JD Guo","year":"2017","unstructured":"Guo JD, O\u2019Flaherty BM, Rainnie DG. Serotonin gating of cortical and thalamic glutamate inputs onto principal neurons of the basolateral amygdala. Neuropharmacology. 2017;126:224\u201332.","journal-title":"Neuropharmacology"}],"updated-by":[{"DOI":"10.1038\/s41380-026-03488-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000}}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03387-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03387-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03387-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T09:03:17Z","timestamp":1776762197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03387-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,20]]},"references-count":86,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["3387"],"URL":"https:\/\/doi.org\/10.1038\/s41380-025-03387-1","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,20]]},"assertion":[{"value":"1 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: In the article above the final sentence of the Abstract should have read \u201cOverall, our research implicates the 5-HT1BR, a non-hallucinogenic serotonin receptor, as a potential mediator of the behavioral and neural effects of psilocybin in mice.\u201d The final sentence of the Introduction should have read \u201cOur findings suggest that the 5-HT1BR influences brain-wide neural changes following psilocybin administration and may contribute to its enduring antidepressant-like effects in mice.\u201d The first sentence of the second paragraph of the Discussion should have read \u201cThough we find that 5-HT1BR contributes to the persisting effects of psilocybin, our data do not address its sufficiency.The original article has been corrected.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41380-026-03488-5","URL":"https:\/\/doi.org\/10.1038\/s41380-026-03488-5","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}